Evidence map›Paper›PMID 40462271›Full record

ArticleJournal of the American Chemical Society2025

A Near-Infrared-II Luminescent and Photoactive Vanadium(II) Complex with a 760 ns Excited State Lifetime.

Alexandra König, Robert Naumann, Christoph Förster, Jan Klett, Katja Heinze

Abstract read
In one paragraph

Article in Journal of the American Chemical Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Redox Chemistry and Photophysics of theInorganic chemistry · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Alexandra KönigDepartment of Chemistry, Johannes Gutenberg University Mainz, Duesbergweg 10-14, Mainz 55128, Germany.
Robert NaumannDepartment of Chemistry, Johannes Gutenberg University Mainz, Duesbergweg 10-14, Mainz 55128, Germany.ORCID 0000-0002-0912-7644
Christoph FörsterDepartment of Chemistry, Johannes Gutenberg University Mainz, Duesbergweg 10-14, Mainz 55128, Germany.ORCID 0000-0003-4971-5368
Jan KlettDepartment of Chemistry, Johannes Gutenberg University Mainz, Duesbergweg 10-14, Mainz 55128, Germany.ORCID 0000-0002-0055-5335
Katja HeinzeDepartment of Chemistry, Johannes Gutenberg University Mainz, Duesbergweg 10-14, Mainz 55128, Germany.ORCID 0000-0003-1483-4156

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ruthenium and iridium are key components in the most important applications of photoactive complexes, namely, light-emitting devices, photocatalysis, bioimaging, biosensing, and photodynamic therapy. Especially, near-infrared (NIR) emissive materials are required in fiber-optic telecommunications, anticounterfeit inks, night-vision readable displays, and bioimaging. Replacing rare and expensive precious metals with more abundant first-row transition metals is of great interest; however, photophysical properties and the chemical stability of 3d metal complexes are often insufficient. Here, we tackle these challenges with a nonprecious metal polypyridine vanadium(II) complex that shows emission above 1300 nm with excited state lifetimes of up to 760 ns. Strong light absorption in the visible spectral region and exceptional stability in the presence of oxygen enable photocatalysis in water and acetonitrile using green to orange-red light for excitation. This study unravels a new design principle for NIR-II luminescent and photoactive complexes based on the abundant first-row transition metal vanadium.

Identifiers

PMID40462271
PMCPMC12186473

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.